Host candidate gene polymorphisms and associated clearance of p. falciparum amodiaquine and fansidar resistance mutants in children less than 5 years in cameroon

Pathogens and Global Health

Volumn 108, Issue 7, 2014, Pages 323-333

  Ali, Innocent Mbulli ^a   Evehe, Marie Solange Bebandue ^b   Netongo, Palmer Masumbe ^b   Atogho Tiedeu, Barbara ^b   Akindeh Nji, Mbuh ^b   Ngora, Honore ^b   Domkam, Irenee Kamogne ^c   Diakite, Mahamadou ^d   Baldip, Khan ^d   Ranford Cartwright, Lisa ^e   Mimche, Patrice Nsangou ^f   Lamb, Tracey ^f   Mbacham, Wilfred Fon ^b  

^a UNIVERSITY OF DSCHANG   (Cameroon)

^b UNIVERSITY OF YAOUNDÉ I   (Cameroon)

^c Chantal Biya International Reference Centre   (Cameroon)

^d Malaria Research Training Centre   (Mali)

^e UNIVERSITY OF GLASGOW   (United Kingdom)

^f EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Amodiaquine; Drug resistance markers; Fever clearance; Immune response; Interleukin 22; Parasite clearance; Sulphadoxine pyrimethamine

Indexed keywords

AMODIAQUINE; CD36 ANTIGEN; CHEMOKINE; GLUTAMINE; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 22; INTERLEUKIN 4; LYMPHOKINE; MEROZOITE SURFACE PROTEIN 1; MEROZOITE SURFACE PROTEIN 2; PYRIMETHAMINE PLUS SULFADOXINE; TUMOR NECROSIS FACTOR; ANTIMALARIAL AGENT; DRUG COMBINATION; FANASIL, PYRIMETHAMINE DRUG COMBINATION; IL4 PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE; INTERLEUKIN-22; PYRIMETHAMINE; SULFADOXINE;

ANTIMALARIAL DRUG RESISTANCE; ARTICLE; CAMEROON; CHEMOLUMINESCENCE; CHILD; CONTROLLED STUDY; DNA EXTRACTION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEVER; GENE FREQUENCY; GENE SEQUENCE; GENOTYPE; HUMAN; HUMAN CHROMOSOME; IMMUNE RESPONSE GENE; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; PLASMODIUM FALCIPARUM; POINT MUTATION; POLYMERASE CHAIN REACTION; RANDOMIZED CONTROLLED TRIAL; RESTRICTION MAPPING; SINGLE NUCLEOTIDE POLYMORPHISM; DRUG COMBINATION; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; INFANT; MALARIA FALCIPARUM; MALE; NEWBORN; PARASITOLOGY; PRESCHOOL CHILD;

AMODIAQUINE; ANTIMALARIALS; CAMEROON; CHILD, PRESCHOOL; DRUG COMBINATIONS; DRUG RESISTANCE; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INFANT; INFANT, NEWBORN; INTERLEUKIN-4; INTERLEUKINS; MALARIA, FALCIPARUM; MALE; PLASMODIUM FALCIPARUM; POLYMORPHISM, SINGLE NUCLEOTIDE; PYRIMETHAMINE; SULFADOXINE;

EID: 84920023241     PISSN: 20477724     EISSN: 20477732     Source Type: Journal    
DOI: 10.1179/2047773214Y.0000000159     Document Type: Article

References (44)

1. Hyde J. Drug-resistant malaria. Trends Parasitol. 2005;21(11): 494-8.
2. Olliaro P, Trigg P. Status of antimalarial drugs under development. Bull World Health Org. 1995;73(5):565-71.
3. Okell L, Drakeley C, Ghani A, Bousema T, Sutherland C. Reduction of transmission from malaria patients by artemisinin combination therapies: a pooled analysis of six randomized trials. Malar J. 2008;7:125.
4. Krishna S, Uhlemann A, Haynes R. Artemisinins: mechanisms of action and potential for resistance. Drug Resistance Updates. 2004;7(4-5):233-44.
5. Nosten F, White N. Artemisinin-based combination treatment of falciparum malaria. Am J Trop Med Hyg. 2007;77(Suppl 6):181-92.
6. Sharma Y. Genetic alteration in drug resistance markers of Plasmodium falciparum. Indian J Med Res. 2005;12113-22.
7. Francis D, Nsobya S, Talisuna A, Yeka A, Kamya M, Dorsey G, et al. Geographic differences in antimalarial drug efficacy in Uganda are explained by differences in endemicity and not by known molecular markers of drug resistance. J Infect Dis. 2006;193(7):978-86.
8. Alifrangis M, Khalil I, Enosse S, Thompson R, Tarimo D, Rønn A, et al. Prediction of Plasmodium falciparum resistance to sulfadoxine/pyrimethamine in vivo by mutations in the dihydrofolate reductase and dihydropteroate synthetase genes: a comparative study between sites of differing endemicity. Am J Trop Med Hyg. 2003;69(6):601-6.
9. Mawili-Mboumba D, Borrmann S, Cavanagh D, McBride J, Matsiegu P, Ntoumi F, et al. Antibody responses to Plasmodium falciparum Merozoite surface protein-1 and efficacy of amodiaquine in gabonese children with P. falciparum malaria. J Infect Dis. 2003;7:1137.
10. Iriemenam N, Okafor C, Balogun H, Hagstedt M, TroyeBlomberg M, Persson J, et al. Cytokine profiles and antibody responses to Plasmodium falciparum malaria infection in individuals living in Ibadan, southwest Nigeria. Afr Health Sci. 2009;9(2):66-74.
11. Sinha S, Qidwai T, Kanchan K, Jha G, Venkatesh V, Sharma S, et al. Variations in host genes encoding adhesion molecules and susceptibility to falciparum malaria in India. Malar J. 2008;7:250.
12. Driss A, Hibbert J, Wilson N, Iqbal S, Adamkiewicz T, Stiles J. Genetic polymorphisms linked to susceptibility to malaria. Malar J. 2011;10:271.
13. Mohan K, Sam H, Stevenson M. Therapy with a combination of low doses of interleukin 12 and chloroquine completely cures blood-stage malaria, prevents severe anemia, and induces immunity to reinfection. Infect Immun. 1999;67(2):513-9.
14. Modiano D, Luoni G, Sirima B, Lanfrancotti A, Petrarca V, Coluzzi M, et al. The lower susceptibility to Plasmodium falciparum malaria of Fulani of Burkina Faso (west Africa) is associated with low frequencies of classic malaria-resistance genes. Trans R Soc Trop Med Hyg. 2001;95(2):149-52.
15. Kabyemela E, Morrison R, Gwamaka M, Fried M, Duffy P, Kurtis J, et al. Cytokine profiles at birth predict malaria severity during infancy. PLoS ONE. 2013;8(10):e77214.
16. Rihet P, Aucan C, Fumoux F, Traoré Y, Traoré-Leroux T, Abel L. Malaria in humans: Plasmodium falciparum blood infection levels are linked to chromosome 5q31-q33. Am J Hum Genet. 1998;63(2):498-505.
17. World Health Organization. Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria. Geneva: WHO; 2003.
18. Mbacham W, Evehe M, Netongo P, Ateh I, Mimche P, Greenwood B, et al. Efficacy of amodiaquine, sulphadoxinepyrimethamine and their combination for the treatment of uncomplicated Plasmodium falciparum malaria in children in Cameroon at the time of policy change to artemisinin-based combination therapy. Malar J. 2010;9:34-42.
19. Wooden J, Gould E, Paull A, Sibley C. Plasmodium falciparum: a simple polymerase chain reaction method for differentiating strains. Exp Parasitol. 1992;75(2):207-12.
20. Pearce R, Drakeley C, Chandramohan D, Roper C, Mosha F. Molecular determination of point mutation haplotypes in the dihydrofolate reductase and dihydropteroate synthase of Plasmodium falciparum in three districts of Northern Tanzania. Antimicrob Agents Chemother. 2003;47(4):1347-54
21. Ahn S, Costa J, Emanuel J. PicoGreen quantitation of DNA: effective evaluation of samples preor post-PCR. Nucleic Acids Res. 1996;24(13):2623-5.
22. Zhang L, Cui X, Schmitt K, Hubert R, Navidi W, Arnheim N. Whole genome amplification from a single cell: implications for genetic analysis. Proc Natl Acad Sci USA. 1992;13:5847
23. Lewis CM, Knight J. Introduction to genetic association studies. Cold Spring Harbor Protoc. 2012;2012:297-306
24. Plowe C, Roper C, Barnwell J, Happi C, Joshi H, Rosenthal P, et al. World Antimalarial Resistance Network (WARN) III: molecular markers for drug resistant malaria. Malar J. 2007;6:121-10.
25. Dorsey G, Staedke S, Gasasira A, Kamya M, Machekano R, Hubbard A. The impact of age, temperature, and parasite density on treatment outcomes from antimalarial clinical trials in Kampala, Uganda. Am J Trop Med Hyg. 2004;71(5):531-6
26. Spolski R, Leonard W. Cytokine mediators of Th17 function. Eur J Immunol. 2009;39(3):658-61.
27. Fouser L, Wright J, Dunussi-Joannopoulos K, Collins M. Th17 cytokines and their emerging roles in inflammation and autoimmunity. Immunol Rev. 2008;226(1):87-102
28. Missé D, Oblet C, Gonzalez J, Veas F, Yssel H, Mazzotta F, et al. IL-22 participates in an innate anti-HIV-1 host-resistance network through acute-phase protein induction. J Immunol. 2007;178(1):407-15.
29. Hennig B, Frodsham A, Hellier S, Knapp S, Yee L, Hill A, et al. Influence of IL-10RA and IL-22 polymorphisms on outcome of hepatitis C virus infection. Liver Int. 2007;27(8):1134-43
30. Morrot A, Hafalla J, Cockburn I, Carvalho L, Zavala F. IL-4 receptor expression on CD8z T cells is required for the development of protective memory responses against liver stages of malaria parasites. J Exp Med. 2005;202(4):551-60.
31. Xie M, Aggarwal S, Ho W, Foster J, Zhang Z, Gurney A, et al. Interleukin (IL)-22, a novel human cytokine that signals through the interferon receptor-related proteins CRF2-4 and IL-22R. J Biol Chem. 2000;275(40):31335-9.
32. Bostrom S, Giusti P, Arama C, Persson J, Dara V, TroyeBlomberg M, et al. Changes in the levels of cytokines, chemokines and malaria-specific antibodies in response to Plasmodium falciparum infection in children living in sympatry in Mali. Malar J. 2012;11:109.
33. Luoni G, Verra F, Coluzzi M, Sirima B, Troye-Blomberg M, Modiano D, et al. Antimalarial antibody levels and IL4 polymorphism in the Fulani of West Africa. Genes Immun. 2001;2(7):411-4.
34. Verra F, Mangano V, Modiano D. Genetics of susceptibility to Plasmodium falciparum: from classical malaria resistance genes towards genome-wide association studies. Parasite Immunol. 2009;31(5):234-53.
35. Eid N, Hussein A, Elzein A, Mohamed H, Rockett K, Ibrahim M, et al. Candidate malaria susceptibility/protective SNPs in hospital and population-based studies: the effect of substructuring. Malar J. 2010;9:119.
36. Borrmann S, Matsiegui P, Missinou M, Kremsner P. Effects of Plasmodium falciparum parasite population size and patient age on early and late parasitological outcomes of antimalarial treatment in children. Antimicrob Agents Chemother. 2008;52(5):1799-805.
37. Djimdé A, Doumbo O, Traore O, Guindo A, Kayentao K, Plowe C, et al. Clearance of drug-resistant parasites as a model for protective immunity in Plasmodium falciparum malaria. Am J Trop Med Hyg. 2003;69(5):558-63.
38. Ferreira P, Holmgren G, Veiga M, Uhlén P, Kaneko A, Pedro Gil J. PfMDR1: mechanisms of transport modulation by functional polymorphisms. PLoS ONE. 2011;6(9):1-8
39. Fry A, Ghansa A, Small K, Auburn S, Diakite M, Rogers W, et al. Positive selection of a CD36 nonsense variant in subSaharan Africa, but no association with severe malaria phenotypes. Hum Mol Genet. 2009;18(14):2683-92.
40. Aitman T, Cooper L, Norsworthy P, Wahid F, Gray J, Hill A, et al. Malaria susceptibility and CD36 mutation. Nature. 2000;405(6790):1015-6.
41. Kajeguka D, Mwanziva C, Chilongola J, Daou M, Ndaro A, Dolmans W, et al. CD36 c.1264 T.G null mutation impairs acquisition of IgG antibodies to Plasmodium falciparum MSP119 antigen and is associated with higher malaria incidences in Tanzanian children. Scand J Immunol. 2012;75(3):355-60.
42. Terlouw D, Aidoo M, Udhayakumar V, Kolczak M, Oloo A, ter Kuile F, et al. Increased efficacy of sulfadoxine-pyrimethamine in the treatment of uncomplicated falciparum malaria among children with sickle cell trait in western Kenya. J Infect Dis. 2002;186(11):1661-8.
43. Venkatesan M, Gadalla N, Stepniewska K, Dahal P, Nsanzabana C, Sibley C, et al. Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunateamodiaquine. Am J Trop Med Hyg. 2014;91(4):833-43.
44. Shi Q, Pavey E, Carter R. Bonferroni-based correction factor for multiple, correlated endpoints. Pharm Stat. 2012;11(4):300-9.